News | December 21, 2023
AGC invests US$ 348 million to expand its biopharmaceutical CDMO capability
Development services for gene and cell therapies is planned to begin first in 2025
Development services for gene and cell therapies is planned to begin first in 2025
Five batches across four programs of Biocon Academy participated in the graduation ceremony
Studies have demonstrated that ZYIL1 is highly potent and can suppress inflammation caused by NLRP3 inflammasome activation
Lacosamide is indicated to treat partial-onset seizures
Darunavir is a protease inhibitor antiviral medicine that prevents Human Immunodeficiency Virus (HIV-1) from multiplying in the body
Cyclophosphamide is a chemotherapy medication that slows the growth of cancer cell
Biocon Biologics is one among the three pharmaceutical companies from India to be featured on this year's list
Announces changes in the commercial organization to incorporate Seagen and improve focus, speed and execution
The exclusive agreement also includes development, regulatory, and commercialization milestone payments based on the successful outcome
New facility is part of Aptar Pharma’s global expansion program
Subscribe To Our Newsletter & Stay Updated
